NCT04515641View on ClinicalTrials.gov

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

September 13, 2021

Study Completion Date

September 13, 2021

Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
DRUG

Islatravir

Two ISL 30 mg capsules taken by mouth.

Trial Locations (1)

33014

Clinical Pharmacology of Miami ( Site 0001), Miami

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04515641 - Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030) | Biotech Hunter | Biotech Hunter